These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Incorporation of a recirculating mobile lipid pool description into the cyclic volatile siloxane (cVMS) PBPK model captures terminal clearance of D Campbell J; Andersen M; Gentry R; Landingham CV; Clewell H Toxicol Lett; 2023 Feb; 375():29-38. PubMed ID: 36596351 [TBL] [Abstract][Full Text] [Related]
6. Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models. Sarangapani R; Teeguarden J; Andersen ME; Reitz RH; Plotzke KP Toxicol Sci; 2003 Jan; 71(1):41-52. PubMed ID: 12520074 [TBL] [Abstract][Full Text] [Related]
7. Development of an integrated multi-species and multi-dose route PBPK model for volatile methyl siloxanes - D4 and D5. McMullin TS; Yang Y; Campbell J; Clewell HJ; Plotzke K; Andersen ME Regul Toxicol Pharmacol; 2016 Feb; 74 Suppl():S1-13. PubMed ID: 26724268 [TBL] [Abstract][Full Text] [Related]
8. Inhalation toxicology of octamethylcyclotetrasiloxane (D4) following a 3-month nose-only exposure in Fischer 344 rats. Burns-Naas LA; Meeks RG; Kolesar GB; Mast RW; Elwell MR; Hardisty JF; Thevenaz P Int J Toxicol; 2002; 21(1):39-53. PubMed ID: 11936898 [TBL] [Abstract][Full Text] [Related]
9. Refinement of the oral exposure description in the cyclic siloxane PBPK model for rats and humans: Implications for exposure assessment. Campbell JL; Andersen ME; Van Landingham C; Gentry R; Jensen E; Domoradzki JY; Clewell HJ Toxicol Lett; 2017 Oct; 279 Suppl 1():125-135. PubMed ID: 28408153 [TBL] [Abstract][Full Text] [Related]
10. Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. Sarangapani R; Teeguarden J; Plotzke KP; McKim JM; Andersen ME Toxicol Sci; 2002 Jun; 67(2):159-72. PubMed ID: 12011475 [TBL] [Abstract][Full Text] [Related]
11. Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Reddy MB; Andersen ME; Morrow PE; Dobrev ID; Varaprath S; Plotzke KP; Utell MJ Toxicol Sci; 2003 Mar; 72(1):3-18. PubMed ID: 12604830 [TBL] [Abstract][Full Text] [Related]
12. Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans. Reddy MB; Dobrev ID; McNett DA; Tobin JM; Utell MJ; Morrow PE; Domoradzki JY; Plotzke KP; Andersen ME Toxicol Sci; 2008 Oct; 105(2):275-85. PubMed ID: 18583370 [TBL] [Abstract][Full Text] [Related]
15. Toxicology and humoral immunity assessment of octamethylcyclotetrasiloxane (D4) following a 28-day whole body vapor inhalation exposure in Fischer 344 rats. Klykken PC; Galbraith TW; Kolesar GB; Jean PA; Woolhiser MR; Elwell MR; Burns-Naas LA; Mast RW; McCay JA; White KL; Munson AE Drug Chem Toxicol; 1999 Nov; 22(4):655-77. PubMed ID: 10536755 [TBL] [Abstract][Full Text] [Related]
16. Biological relevance of effects following chronic administration of octamethylcyclotetrasiloxane (D4) in Fischer 344 rats. Dekant W; Scialli AR; Plotzke K; Klaunig JE Toxicol Lett; 2017 Oct; 279 Suppl 1():42-53. PubMed ID: 28109826 [TBL] [Abstract][Full Text] [Related]
17. Assessing modes of action, measures of tissue dose and human relevance of rodent toxicity endpoints with octamethylcyclotetrasiloxane (D4). Andersen ME Toxicol Lett; 2022 Mar; 357():57-72. PubMed ID: 34995712 [TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling of the disposition of octamethylcyclotetrasiloxane (D4) migration from implants in humans. Thrall KD; Soelberg JJ; Powell T; Corley RA J Long Term Eff Med Implants; 2008; 18(2):133-44. PubMed ID: 19968622 [TBL] [Abstract][Full Text] [Related]